Standard BioTools

Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. The company is headquartered in Boston, Massachusetts and currently employs 385 full-time employees. The company went IPO on 2011-02-10. The firm develops, manufactures and sells a diversified range of instrumentation, consumables, and services. The firm's Genomics business includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. Its Biomark X9 system for high-throughput genomics delivers scalability for qPCR applications. Designed for researchers who require robust multiplexing capabilities, the Biomark X9 system enables the simultaneous analysis of thousands of reactions in a single run. By leveraging advanced microfluidics technology, it reduces reagent consumption while increasing throughput, making it a solution for large-scale genomic studies, clinical research, and biomarker discovery. The Biomark X9 system integrates with data analysis tools, accelerating workflows and providing comprehensive insights.